BRISBANE, Calif., Dec. 22, 2014 (GLOBE NEWSWIRE) -- Cutera, Inc. (Nasdaq:CUTR), a leading provider of laser, light and other energy-based aesthetic systems for practitioners worldwide, announced that it started its first customer shipments and deliveries of its picosecond laser platform, enlighten, which is 510(k) cleared by the U.S. Food and Drug Administration for tattoo removal and the treatment of benign pigmented lesions.
"Commencing customer shipments marks an important milestone in the commercialization of our enlighten picosecond laser system. Cutera's engineering, clinical, and manufacturing teams brought this leading technology platform to market with unprecedented speed. From the initial research and development work and then the completion of the pivotal US FDA study and clearance, the shipment and delivery of systems to customers represents a tremendous accomplishment for the company. We are very pleased to have a backlog of enlighten orders, and thank our customers for their support and belief in this important technology," said Kevin Connors, President and CEO of Cutera, Inc.
About Cutera, Inc.
Brisbane, California-based Cutera is a leading provider of laser and other energy-based aesthetic systems for practitioners worldwide. Since 1998, Cutera has been developing innovative, easy-to-use products that enable physicians and other qualified practitioners to offer safe and effective aesthetic treatments to their patients. For more information, call 1-888-4CUTERA or visit www.cutera.com.
This press release contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Specifically, statements concerning the features, effectiveness, treatable conditions, and timing of commercial sales are forward-looking statements within the meaning of the Safe Harbor. Such forward-looking statements are subject to risks and uncertainties and may be affected by various factors that may cause actual results to differ materially from those in the forward-looking statements and those other factors described in the section entitled, "Risk Factors", in Cutera's most recent Form 10-Q as filed with the Securities and Exchange Commission on November 3, 2014. Undue reliance should not be placed on forward-looking statements, which speak only as of the date they are made. Cutera undertakes no obligation to update publicly any forward-looking statements to reflect new information, events or circumstances after the date they were made, or to reflect the occurrence of unanticipated events.
CONTACT: Cutera, Inc. Ron Santilli Chief Financial Officer 415-657-5500 Investor Relations John Mills Integrated Corporate Relations, Inc. 310-954-1105 email@example.com